ARS Pharmaceuticals board member resigns, chief medical officer departs

ARS Pharmaceuticals, Inc. disclosed in a Form 8-K dated July 15, 2026 that Richard Lowenthal resigned as a member of the Board of Directors of the company, effective immediately.¹ The filing states that his resignation from the board was a condition of his right to receive severance compensation under his employment agreement and the company's Change in Control and Severance Benefit Plan, as described in the company's proxy statement filed with the SEC on April 29, 2026.¹

The same filing reports that Sarina Tanimoto, M.D., the company's Chief Medical Officer, ceased employment with the company under conditions constituting a termination without cause on July 15, 2026.¹

Beyond the severance terms outlined in the proxy statement, the company said it agreed to make one-time cash payments to both departing executives. The amounts were $217,350 to Lowenthal and $111,780 to Tanimoto, representing prorated portions of their target bonuses for 2026.¹ These payments, along with the severance benefits already described in the proxy statement, are contingent: both are conditioned on each executive signing a release of claims in favor of the company.¹

The 8-K was signed on July 17, 2026 by Donn Casale, President and Chief Executive Officer of ARS Pharmaceuticals. The filing does not disclose whether replacements for the board seat or the chief medical officer role have been identified.